Novavax Statistics
Total Valuation
Novavax has a market cap or net worth of $1.46 billion. The enterprise value is $968.23 million.
Important Dates
The last earnings date was Wednesday, May 6, 2026, before market open.
| Earnings Date | May 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Novavax has 164.44 million shares outstanding. The number of shares has increased by 0.58% in one year.
| Current Share Class | 164.44M |
| Shares Outstanding | 164.44M |
| Shares Change (YoY) | +0.58% |
| Shares Change (QoQ) | -1.15% |
| Owned by Insiders (%) | 0.84% |
| Owned by Institutions (%) | 58.76% |
| Float | 141.47M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.45 |
| Forward PS | 4.34 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.62 |
| EV / EBITDA | 16.26 |
| EV / EBIT | 26.03 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.48
| Current Ratio | 2.48 |
| Quick Ratio | 2.38 |
| Debt / Equity | n/a |
| Debt / EBITDA | 4.34 |
| Debt / FCF | n/a |
| Interest Coverage | 1.65 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 1.99% |
| Return on Invested Capital (ROIC) | 15.33% |
| Return on Capital Employed (ROCE) | 5.31% |
| Weighted Average Cost of Capital (WACC) | 15.39% |
| Revenue Per Employee | $796,179 |
| Profits Per Employee | -$117,270 |
| Employee Count | 749 |
| Asset Turnover | 0.51 |
| Inventory Turnover | 39.81 |
Taxes
In the past 12 months, Novavax has paid $1.65 million in taxes.
| Income Tax | 1.65M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +32.24% in the last 52 weeks. The beta is 2.37, so Novavax's price volatility has been higher than the market average.
| Beta (5Y) | 2.37 |
| 52-Week Price Change | +32.24% |
| 50-Day Moving Average | 8.90 |
| 200-Day Moving Average | 8.32 |
| Relative Strength Index (RSI) | 50.65 |
| Average Volume (20 Days) | 5,389,641 |
Short Selling Information
The latest short interest is 49.48 million, so 30.09% of the outstanding shares have been sold short.
| Short Interest | 49.48M |
| Short Previous Month | 46.34M |
| Short % of Shares Out | 30.09% |
| Short % of Float | 34.97% |
| Short Ratio (days to cover) | 15.57 |
Income Statement
In the last 12 months, Novavax had revenue of $596.34 million and -$87.84 million in losses. Loss per share was -$0.54.
| Revenue | 596.34M |
| Gross Profit | 163.96M |
| Operating Income | 37.20M |
| Pretax Income | -86.19M |
| Net Income | -87.84M |
| EBITDA | 59.53M |
| EBIT | 37.20M |
| Loss Per Share | -$0.54 |
Full Income StatementBalance Sheet
The company has $790.33 million in cash and $295.06 million in debt, with a net cash position of $495.27 million or $3.01 per share.
| Cash & Cash Equivalents | 790.33M |
| Total Debt | 295.06M |
| Net Cash | 495.27M |
| Net Cash Per Share | $3.01 |
| Equity (Book Value) | -144.76M |
| Book Value Per Share | -0.88 |
| Working Capital | 508.36M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$91.56 million and capital expenditures -$5.24 million, giving a free cash flow of -$96.79 million.
| Operating Cash Flow | -91.56M |
| Capital Expenditures | -5.24M |
| Depreciation & Amortization | 22.34M |
| Net Borrowing | 80.57M |
| Free Cash Flow | -96.79M |
| FCF Per Share | -$0.59 |
Full Cash Flow StatementMargins
Gross margin is 27.49%, with operating and profit margins of 6.24% and -14.73%.
| Gross Margin | 27.49% |
| Operating Margin | 6.24% |
| Pretax Margin | -14.45% |
| Profit Margin | -14.73% |
| EBITDA Margin | 9.98% |
| EBIT Margin | 6.24% |
| FCF Margin | n/a |
Dividends & Yields
Novavax does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.58% |
| Shareholder Yield | -0.58% |
| Earnings Yield | -6.00% |
| FCF Yield | -6.61% |
Analyst Forecast
The average price target for Novavax is $14.11, which is 58.54% higher than the current price. The consensus rating is "Buy".
| Price Target | $14.11 |
| Price Target Difference | 58.54% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | -0.48% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 10, 2019. It was a reverse split with a ratio of 1:20.
| Last Split Date | May 10, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
Novavax has an Altman Z-Score of -4.23 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.23 |
| Piotroski F-Score | 2 |
